康艾注射液联合化疗治疗晚期卵巢癌临床观察

目的 探讨康艾注射液在晚期卵巢癌化疗中的使用效果及不良反应.方法 64例晚期卵巢癌患者随机分为实验组、对照组两组,实验组(32例)采用康艾注射液联合DC(多西他赛+卡铂)方案治疗,对照组(32例)采用单纯DC方案化疗,评价两组治疗效果、生存质量、不良反应及免疫状态.结果 实验组与对照组的客观缓解率比较,差异无统计学意义(P＞0.05),两组的疾病控制率(CR+PR+SD)比较,差异有统计学意义(P＜ 0.05),实验组中位生存期为40周,对照组中位生存期为31周,实验组治疗后T淋巴细胞亚群中的CD4/CD8比值有显著提高(P＜0.05),对照组治疗后T淋巴细胞亚群中的CD4/CD8比值有明显降低(P＜0.05),生存质量实验组高于对照组(P＜0.05),白细胞减少和消化道反应对照组高于实验组(P＜0.05).结论 应用康艾注射液联合化疗治疗晚期卵巢癌能减轻化疗某些不良反应、提高临床获益率、延长中位生存时间、改善生存质量和免疫功能.

Kang'ai injection combined with chemotherapy for advanced ovarian cancer

Objective To explore the effect and side effect of Kang'ai injection incompchemotherapy for advanced ovarian cancer.Methods 64 patients with advanced ovarian cancer were randomly divided into an experimental group and a control group,32 for each group.The experimental group were treated with Kang'ai injection and DC chemotherapy and the control group DC chemotherapy.The treatment effect,survival quality,adverse reactions,and immunologic conditions were evaluated in both groups.Results The objective response rate (CR+PR) was 39.2％ in the experimental group and 30.6％ in the control group (P ＞ 0.05).The disease control rate (CR+PR+SD) was 86.2％ in the experimental group and 40.8％ in the control group (P ＜ 0.05).The median survival time was 40 weeks in the experimental group and 31 weeks in the control group (P ＜ 0.05).The CD4/CD8 was significantly increased in the experimental group (P ＜ 0.05) and significantly decreased in the control group(P ＜ 0.05).The survival quality was higher in the experimental group than in the control group (P ＜ 0.05).The leucopenia,nausea,and vomiting were more serious in the control group than in the experimental group (P ＜ 0.05).Conclusions Kangai injection combined with chemotherapy for advanced ovarian cancer can decrease some side effects of chemotherapy,increase clinical benefit response rate,elongate median survival time,and improve the patients' survival quality and immune function.